NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq: NRXP) reported Q1 2026 results and key pipeline advances. Net loss was $1.4 million, versus $5.5 million a year earlier, with operating loss of $4.7 million. Cash was $6.7 million on March 31, 2026, plus about $7 million raised post-quarter via an ATM facility.
NRx advanced its preservative-free ketamine ANDA toward an anticipated FDA decision in Q3 2026 and began commercial-scale manufacturing. It progressed NRX-101 in suicidal bipolar depression and as a TMS adjunct, expanded HOPE Therapeutics clinics, and moved toward acquiring Geneuro Phase 2 HERV-targeted assets.
AI-generated analysis. Not financial advice.
Positive
- Net loss reduced to $1.4M from $5.5M year-over-year
- First revenue generated from five interventional psychiatry clinics
- Ketamine ANDA review advancing; FDA VAI status enables large-scale manufacturing
- IND accepted for NRX-101 MIND1 TMS adjunct trial with anticipated federal funding
- Pending Geneuro HERV asset acquisition funded from prefunded escrow, expected Q2 2026 close
- Approximately $7M raised after quarter-end via at-the-market stock sales
Negative
- Operating loss increased to $4.7M from $3.8M year-over-year
- Cash and cash equivalents of $6.7M as of March 31, 2026
News Market Reaction – NRXP
On the day this news was published, NRXP declined 5.03%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -15.4% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $108.46M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NRXP gained 2.18% while close peers showed mixed moves (e.g., SLGL up 5.82%, ABVC up 1.85%, VANI down 2.5%, IMMX down 0.9%, MGX down 1.5%). Momentum scanner flagged other names like VANI and ANL moving up, but this pattern does not indicate a coordinated sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | Q3 2025 earnings | Neutral | -15.3% | Reported higher operating loss but first revenue from Dura Medical acquisition. |
| Aug 18 | Q2 2025 earnings | Negative | -4.5% | Larger net loss and low cash despite Fast Track expansion and new investment. |
| Aug 13 | Earnings reschedule | Negative | +5.5% | Delay of Q2 2025 results release to August 19, 2025 for more preparation time. |
| May 15 | Q1 2025 earnings | Positive | +2.1% | Improved net loss, pipeline progress, and expansion plans for HOPE clinics. |
| Mar 17 | FY 2024 results | Neutral | -12.8% | Reduced annual operating loss and cost cuts alongside ongoing net losses. |
Earnings releases have often produced downside moves, especially when losses or financing needs were emphasized, though positive operational updates sometimes muted the impact.
Over the past year, NRx’s earnings events have combined financial updates with significant regulatory and clinical milestones. Prior quarters highlighted advancing NRX-100 and NRX-101, Fast Track designations, and expansion of HOPE Therapeutics’ clinic network, alongside recurring net losses and modest cash balances. Reactions were mixed: some reports with deeper losses saw sharp declines, while updates featuring pipeline progress and clinic expansion occasionally aligned with modest gains. Today’s Q1 2026 results continue this pattern of pairing loss metrics with tangible steps toward commercialization and clinic-driven revenue growth.
Historical Comparison
Past earnings-related releases for NRXP saw an average move of -4.98%. Today’s 2.18% gain versus prior close represents a milder, more positive reaction than typical for this news type.
Across recent earnings cycles, NRx has repeatedly paired loss metrics with steady advancement of NRX-100, NRX-101, and expansion of HOPE Therapeutics clinics, gradually shifting its narrative toward commercialization and integrated clinic-pharma operations.
Regulatory & Risk Context
An effective S-3/A shelf dated Dec 12, 2025 allows the company to offer up to $150,000,000 of various securities, with $78,644,060 carried over from a prior registration. No 424B usage is recorded yet, but the shelf provides flexibility to raise capital to support working capital and growth as described in the filing.
Market Pulse Summary
The stock moved -5.0% in the session following this news. A negative reaction despite operational progress would fit prior earnings patterns, where updates averaging -4.98% often coincided with focus on losses and funding needs. Q1 2026 still showed a $4.7 million operating loss and modest $6.7 million cash, even with post-quarter ATM proceeds of $7 million. An effective $150 million shelf provides flexibility but can weigh on sentiment when markets focus on potential dilution.
Key Terms
nda regulatory
real world evidence medical
transcranial magnetic stimulation (tms) medical
phase 2b/3 medical
at-the-market offering financial
human endogenous retroviruses (hervs) medical
AI-generated analysis. Not financial advice.
Key highlights from the first quarter of operations under the expanded management team include the following:
- Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable preliminary determinations already received from the FDA Office of Generic Drugs on bioequivalence, labeling, drug product, drug substance, and safety.
- Initiation of commercial manufacturing of Ketamine at the 1 million dose per month level with recent FDA inspection of the manufacturing facility and granting of inspection status consistent with launch of an ANDA drug.
- Completed a Type C meeting with the FDA Division of Psychiatry Products and CDER leadership, in which the Agency expressed openness to existing clinical trial data and Real World Evidence supporting approval without additional trials.
- Presidential Executive Order signed and Congressional Appropriations Language filed encouraging the use of Real World Evidence in the approval of drugs for suicidal depression and PTSD.
- Appointment of Prof. Joshua Brown, MD, PhD (Harvard/McLean) as Chief Medical Innovation Officer, bringing NIH- and DARPA-funded expertise in D-cycloserine and TMS for depression, PTSD, and suicidality.
- FDA acceptance of an Investigational New Drug (IND) application for NRX-101 as an adjunct to robotic-enabled Transcranial Magnetic Stimulation (TMS), with anticipated non-dilutive federal funding supporting study at military and civilian sites.
- Development of a patentable, sustained-release formulation of D-cycloserine designed to enhance TMS efficacy, building on prior trial data showing a doubling of clinical response and 8-fold increase in remission versus standard TMS.
- First revenue generated from five interventional psychiatry clinics treating severe depression and PTSD, with funding from the VA, Department of War, private insurers, and self-pay; footprint expected to expand meaningfully in 2026.
- Pending acquisition of Geneuro, SA assets through a now complete Swiss court-supervised liquidation process, including a patent portfolio, antibodies, cell lines, and Phase 2 data targeting HERVs implicated in Schizophrenia, ALS, MS, Autism, and Type 1 Diabetes.
WILMINGTON, Del., May 18, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2026, and provided a corporate update. The quarter was marked by continued progress advancing NRx’s drug candidates toward commercialization, further development of the HOPE Therapeutics subsidiary, FDA acceptance of an IND for a federally-supported trial of NRX-101 as an adjunct to robotic Transcranial Magnetic Stimulation (TMS), and the pending acquisition of a Phase 2 monoclonal antibody portfolio targeting Human Endogenous Retroviruses (HERVs) implicated in Schizophrenia, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Autism, and Type 1 Diabetes.
“The first quarter of 2026 was a pivotal one for NRx, as we advanced two lifesaving drugs towards FDA approval with the aim of initiating commercial pharmaceutical operations by the end of this year. We started the year debt-free, and made targeted investments in several critical strategic operating initiatives that drove 1) substantial progress toward the approval of our first drug product, 2) initiated commercial manufacture in anticipation of drug launch, 3) advanced profitable clinic operations with an expanded footprint, 4) burgeoned our overall intellectual property portfolio, 5) augmented our development pipeline and 6) attracted fundamental long-term investors who believe in our mission,” said Dr. Jonathan Javitt, the Company’s CEO and Chairman. “We are deeply grateful for the trust that has been afforded to us by our patients, their families, and our shareholders.”
Key Research and Development and Corporate Activities
NRX-100 and KETAFREE™ (Preservative-Free Ketamine)
NRx advanced both regulatory pathways for its preservative-free ketamine programs during the quarter. The KETAFREE™ ANDA progressed through FDA Office of Generic Drugs review with no major deficiencies, and the FDA reclassified the manufacturing site to "VAI" status, enabling the Company to initiate commercial manufacturing at a one-million-unit-per-batch scale. FDA is endeavoring to complete the product review by Summer 2026. As of April 7, 2026, sterile intravenous ketamine remained listed on the American Society of Health-System Pharmacists (ASHP) national drug shortage database, with ongoing supply constraints reported across multiple manufacturers, underscoring the need for additional reliable, domestically manufactured ketamine supply. The NRX-100 NDA, expected to be filed in Q2 2026, will be supported by clinical trial evidence in more than 1,000 patients and Real World Evidence on more than 65,000 U.S. patients through a partnership with Osmind, Inc. Following a Type C meeting, the FDA agreed to consider both data sources in its review. Management believes that the current generic ketamine market exceeds
NRX-101 (D-cycloserine/lurasidone)
NRX-101 advanced on two tracks during the quarter. In its original indication of suicidal bipolar depression, the Company initiated an NDA filing with submission of the Module 3 manufacturing file and is requesting rolling review, building on Breakthrough Therapy Designation previously awarded by the FDA. Separately, the Company received FDA clearance to proceed with the MIND1 trial, a Phase 2b/3 study of NRX-101 versus placebo as an adjunct to robotic-assisted Transcranial Magnetic Stimulation in conjunction with an accelerated one-day TMS protocol (ONE-D). The trial is designed to enroll 400 participants across Military Treatment Facilities, HOPE Therapeutics clinics, and a prominent university teaching hospital, with non-dilutive U.S. Government funding anticipated. The Company also achieved non-clinical validation of a proprietary extended-release form of D-cycloserine designed to support TMS augmentation.
NRx Defense Systems, Inc.
To advance its military-focused neuroplastic therapy initiatives, the Company incorporated NRx Defense Systems, Inc. in April 2026 to support the MIND1 trial and broader development of military-grade TMS technology. The subsidiary is led by Dr. Dennis K. McBride, PhD (CAPT US Navy, Ret.), a former Program Manager at DARPA and senior executive at the National Defense University and Office of the Secretary of Defense, with development conducted in partnership with Zeta Surgical (Cambridge, MA).
HOPE Therapeutics, Inc.
HOPE Therapeutics, a majority-owned subsidiary, continued to scale its interventional psychiatry network during the quarter, operating five Florida clinics with eight or more locations anticipated by the end of Q2 2026. In February 2026, HOPE appointed Prof. Joshua Brown, MD, PhD, of Harvard/McLean as Chief Medical Innovation Officer, joining Rebecca Cohen, MD, as Medical Director. The subsidiary further expanded its footprint through partnerships with neurocare AG, focused on NRX-101 as a TMS-enhancing therapy, and EMOBOT, Inc., to deploy continuous patient monitoring across HOPE's clinical network.
Geneuro, Inc.
NRx broadened its therapeutic platform through the formation of Geneuro, Inc., a Florida-based subsidiary focused on the anticipated acquisition of a portfolio of assets targeting Human Endogenous Retroviruses (HERVs) implicated in Schizophrenia, Multiple Sclerosis, ALS, Autism, and Optic Neuritis. The portfolio was offered through a Swiss court-supervised liquidation sale process of Geneuro, SA, and the Company was recently notified that it had submitted the winning bid. The acquisition is expected to close during the second quarter of 2026 with cash in an existing, prefunded escrow account, and includes a broad patent portfolio, cell lines, antibodies, regulatory files, and data from three completed human clinical trials. Dr. Hervé Perron, PhD, formerly Chief Scientist of Geneuro, SA, has joined as Chief Scientist alongside Prof. Marion Leboyer, MD, PhD, who will lead the anti-HERV-W antibody program. The Company anticipates supporting Geneuro through non-dilutive investment channels.
Financial Results for the Quarter Ended March 31, 2026
For the three months ended March 31, 2026, NRx reported a net loss of
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
